LFB-R603 regulatory update

FDA granted Orphan Drug designation for LFB's LFB-R603 to treat chronic lymphocytic leukemia (CLL). The chimeric recombinant mAb against CD20 is in a Phase I/II trial and has Orphan Drug designation ...